AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15673408
Drug: Pexelizumab bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pexelizumab bolus (2.0 mg/kg) + pexelizumab infusion (0.05 mg/kg/hour for 24 hours)
Trial: 15673408
Drug: Placebo bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bolus + placebo infusion
Trial: 12151925
Drug: P6 acupoint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P6 acupoint injections
Trial: 2240495
Drug: Triclofos 70
RxNorm normalized name: Triclofos
DrugBank: Triclofos (DB06753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triclofos 70 mg/kg orally 90 minutes before operation
Trial: 206923
Drug: TZM 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TZM 0.25 mg
Trial: 206923
Drug: FZP 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FZP 15 mg
Trial: 27329506
Drug: Daily intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intermittent hypoxia (IH) combined with body weight-supported treadmill training (BWSTT)
Trial: 26073353
Drug: Amfepramone 75
RxNorm normalized name: Amfépramone
DrugBank: Diethylpropion (DB00937)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amfepramone 75 mg daily for 6 months
Trial: 19251010
Drug: Fentanyl with
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl with midazolam (lower doses 2-3.5 mg)
Trial: 19251010
Drug: Meperidine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine with midazolam (lower doses 2-3.5 mg)
Trial: 19251010
Drug: Fentanyl with
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl with midazolam (higher doses >= 4 mg)
Trial: 19251010
Drug: Meperidine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine with midazolam (higher doses >= 4 mg)
Trial: 10919304
Drug: bupivacaine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 15 mg + morphine 5 mg + intraarticular methylprednisolone 40 mg
Trial: 9010697
Drug: Candoxatril 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candoxatril 25 mg b.i.d.
Trial: 9010697
Drug: Candoxatril 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candoxatril 100 mg b.i.d.
Trial: 9010697
Drug: Candoxatril 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candoxatril 400 mg b.i.d.
Trial: 1490141
Drug: Methylprednisolone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (100 mg/day initially)
Trial: 28211285
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration analgesia (LIA) combined with femoral nerve block (FNB) - 150 mL mixture of ropivacaine 2.0 mg/mL + ketorolac 30 mg + adrenaline 10 μg/mL
Trial: 12972476
Drug: IV ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ibandronate 2 mg
Trial: 12972476
Drug: IV ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ibandronate 1 mg
Trial: 12972476
Drug: IV ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ibandronate 0.5 mg
Trial: 12972476
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of ibandronate
Trial: 10712859
Drug: Clove oil
RxNorm normalized name: Clove Oil
DrugBank: Clove oil (DB11338)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clove oil carrier solution
Trial: 8665577
Drug: MK-462 20
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-462 20 mg
Trial: 8665577
Drug: MK-462 40
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-462 40 mg
Trial: 1388093
Drug: Provera 500-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provera 500-mg tablet
Trial: 1388093
Drug: Farlutal 500-mg
RxNorm normalized name: medroxyprogesterone acetate Injectable Suspension [Farlutal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Farlutal 500-mg tablet
Trial: 1388093
Drug: Provera 500-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provera 500-mg granule packet
Trial: 3916620
Drug: Computer-assisted meal-related
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted meal-related insulin therapy (CAMIT = 3-4 injections daily)
Trial: 3916620
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (CT = 2-3 injections daily)
Trial: 26549402
Drug: Esomeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (40 mg/d)
Trial: 27043753
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (control group with exact copy of text from MCG)
Trial: 2853441
Drug: 1% nedocromil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% nedocromil sodium nasal spray given four times daily for four weeks
Trial: 2853441
Drug: 1% nedocromil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% nedocromil sodium nasal spray
Trial: 27571889
Drug: Interactive web‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive web‐based sleep intervention based on cognitive behavioral therapy principles
Trial: 14761905
Drug: General medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General medicine trials
Trial: 10188788
Drug: CI‐979/RU35926 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI‐979/RU35926 (doses of 0.002-1.0 mg, with cholinergic symptoms observed at 2-4 mg)
Trial: 16956475
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of ketorolac administered intravenously 30 minutes before surgery
Trial: 16956475
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously 30 minutes before surgery
Trial: 9028694
Drug: Levosulpiride (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosulpiride (25 mg t.i.d. orally for 6 months)
Trial: 3303693
Drug: Pharmaxolon treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaxolon treatment for 20 days
Trial: 26952346
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (10 mg/kg)
Trial: 18506387
Drug: Apomorphine (Apo)
DrugBank: Apomorphine (DB00714)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apomorphine (Apo) 7 microg/kg sc, administered in seven injections at 2-hour intervals
Trial: 18506387
Drug: Placebo (physiological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (physiological saline), administered in seven injections at 2-hour intervals
Trial: 14659379
Drug: Qi-therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qi-therapy
Trial: 10774682
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral artemether
Trial: 10774682
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg intramuscular artemether
Trial: 10774682
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg suppository artemether
Trial: 10774682
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral artesunate (Guillin formulation)
Trial: 10774682
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral artesunate (Arenco formulation)
Trial: 10774682
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral dihydroartemisinin
Trial: 6603249
Drug: Erythromycin stearate
RxNorm normalized name: Erythromycin Stearate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin stearate 500 mg every six hours for seven days
Trial: 6603249
Drug: Erythromycin or
RxNorm normalized name: erythromycin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin or placebo preparation for a further week
Trial: 30866943
Drug: Placebo arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm of a double-blind randomized vaccine trial
Trial: 25577869
Drug: Astaxanthin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin (25 mg x kg(‐1) x d(‐1) x bw(‐1)) from day 5 to 20 of pregnancy
Trial: 25577869
Drug: L-NAME (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NAME (125 mg x kg(‐1) x d(‐1) x bw(‐1)) from days 10-20 of pregnancy
Trial: 21295843
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg PGF given 48 h prior to embryo collection (Treated cycle)
Trial: 21295843
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg PGF given at embryo collection (Control cycle)
Trial: 15535485
Drug: Abdominal lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal lavage with normal saline solution (3000 to 6000 ml)
Trial: 11499536
Drug: PUVA (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA (oral 8‐MOP plus UVA)
Trial: 11499536
Drug: PUVB (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVB (oral 8‐MOP plus UVB)
Trial: 8860097
Drug: Diuretics (95%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics (95% thiazides and related agents) with high dietary sugar intake
Trial: 8860097
Drug: Diuretics (95%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics (95% thiazides and related agents) with low dietary sugar intake
Trial: 1512524
Drug: Indobufen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen (400 mg/day)
Trial: 1512524
Drug: Dipyridamole (225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (225 mg/day) plus Acetylsalicylic Acid (1 g/day)
Trial: 30803503
Drug: Freeze-dried bilberry
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze-dried bilberry (40 g/d) and standard medical therapy
Trial: 30803503
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving standard medical therapy alone
Trial: 22338863
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion (AA group, n = 22)
Trial: 22338863
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid and glucose infusion (AAGlu group, n = 18)
Trial: 20207123
Drug: Formula with
RxNorm normalized name: Stress B Formula with C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula with 130 mg DHA per day
Trial: 20207123
Drug: Formula with
RxNorm normalized name: Stress B Formula with C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula with 0 mg DHA per day (control)
Trial: 17221933
Drug: Secnidazole 500
RxNorm normalized name: secnidazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secnidazole 500 mg oral dosage
Trial: 17221933
Drug: Reference secnidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference secnidazole tablets
Trial: 29300100
Drug: UC +
RxNorm normalized name: Astri-UC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UC + CALM ARC (7-session, group-based, computer-assisted but therapist-directed treatment)
Trial: 25917860
Drug: Heated lidocaine/tetracaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heated lidocaine/tetracaine patch
Trial: 11128360
Drug: Combined ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined ramipril treatment
Trial: 11128360
Drug: Ramipril (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (both doses)
Trial: 6374533
Drug: Single 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 150 mg intramuscular dose of netilmicin
Trial: 6374533
Drug: Five-day course
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-day course of oral co-trimoxazole
Trial: 24318410
Drug: Continuous absorbable
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous absorbable intradermal sutures
Trial: 16355647
Drug: Supervised tooth-brushing
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised tooth-brushing with 1.23% APF gel (1 minute once a week)
Trial: 12386505
Drug: Pulmonary artery
RxNorm normalized name: Pulmonary artery blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary artery catheter (PAC) led therapy
Trial: 201440
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg fluoride as NaF in a watery solution
Trial: 201440
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg fluoride in tablet form (D‐Fluoretten 1000)
Trial: 28032641
Drug: Early tumor
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early tumor shrinkage (ETS) observed in first-line treatment
Trial: 28032641
Drug: Early tumor
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early tumor shrinkage (ETS) in second-line therapy
Trial: 28032641
Drug: Minor early
RxNorm normalized name: Vinca minor extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minor early tumor shrinkage (mETS) in second-line therapy
Trial: 28032641
Drug: Minor progression
RxNorm normalized name: Vinca minor extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minor progression (mPD) in second-line therapy
Trial: 28032641
Drug: Progression (PD)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progression (PD) in second-line therapy
Trial: 23660094
Drug: Inosine within
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosine within 6 hours (600 mg twice a day for 10-14 days)
Trial: 23660094
Drug: Inosine after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosine after 6 hours (600 mg twice a day for 10-14 days)
Trial: 23660094
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy group (routine treatments)
Trial: 9667227
Drug: Melatonin (MEL)
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin (MEL) 12 mg orally
Trial: 2657467
Drug: Pyridostigmine 60
RxNorm normalized name: pyRIDostigmine 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine 60 mg orally
Trial: 9667227
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MEL and pyridostigmine
Trial: 9667227
Drug: Naloxone (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (1.2 mg bolus followed by i.v. infusion of 1.6 mg/h for 3 hours)
Trial: 8134442
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy at 2.5 atmospheres for 90 minutes, 5 days per week for 30 treatments
Trial: 8134442
Drug: Air therapy
RxNorm normalized name: Amlactin Foot Repair Therapy 15% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air therapy at 2.5 atmospheres for 90 minutes, 5 days per week for 30 treatments
Trial: 30239456
Drug: Exponential tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exponential tapering (n = 79)
Trial: 30239456
Drug: Linear tapering
RxNorm normalized name: Aspalathus linearis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linear tapering (n = 79)
Trial: 28905498
Drug: Bimagrumab 30
RxNorm normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimagrumab 30 mg/kg i.v.
Trial: 28166861
Drug: Dignity therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dignity therapy (DT) + standard palliative care (SPC)
Trial: 19837300
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of recombinant human erythropoietin (rHuEPO) at 150 IU/kg, 4 doses at 48-hour intervals
Trial: 19837300
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received 0.5 mL/kg isotonic solution
Trial: 12638100
Drug: Heatwrap therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heatwrap therapy
Trial: 9607135
Drug: Intravenous procainamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous procainamide (1 g over 30 minutes, followed by an infusion of 2 mg/min over 1 hour)
Trial: 2243887
Drug: Oral pilocarpine
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pilocarpine (25 mg)
Trial: 354047
Drug: Oxamniquine (Vansil)
RxNorm normalized name: oxamniquine
DrugBank: Oxamniquine (DB01096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxamniquine (Vansil) at an oral dose of 15 mg/kg twice a day for 2 days (total dose 60 mg/kg)
Trial: 31347100
Drug: IDegLira (fixed-ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDegLira (fixed-ratio combination of insulin degludec and liraglutide)
Trial: 28150516
Drug: Alternative insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alternative insulin regimens
Trial: 16402278
Drug: Paclitaxel alone
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel alone (175 mg/m2/IV)
Trial: 16402278
Drug: Paclitaxel with
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel with Tamoxifen (TAM) (160 mg/m2 PO BID on Days 1-5 followed by paclitaxel 175 mg/m2/IV on Day 5)
Trial: 15306531
Drug: Melatonin 3
RxNorm normalized name: melatonin 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 3 mg (n = 12)
Trial: 8353089
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg three times a day for 15 days
Trial: 29923950
Drug: Costoclavicular approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Costoclavicular approach (Gp-CC)
Trial: 27543595
Drug: Standardized daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standardized daptomycin dosing protocol
Trial: 25231685
Drug: Comprehensive pharmacologic
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive pharmacologic cancer pain therapy (CPT)
Trial: 28436380
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF) monotherapy
Trial: 20600025
Drug: Fixed-dose emtricitabine
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fixed-dose emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) combination therapy
Trial: 23939953
Drug: TDF monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF monotherapy
Trial: 20600025
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (FTC/TDF)
Trial: 8874257
Drug: diuretic responsive
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diuretic responsive (group A; n = 6)
Trial: 8874257
Drug: diuretic resistant
RxNorm normalized name: benazepril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diuretic resistant (group B; n = 23)
Trial: 15310639
Drug: Caudal 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal 0.25% plain bupivacaine 0.5 mL.kg(‐1)
Trial: 15310639
Drug: Caudal 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal 0.25% plain bupivacaine 0.5 mL.kg(‐1) with neostigmine 2 microg.kg(‐1)
Trial: 15310639
Drug: Caudal 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal 0.25% plain bupivacaine 0.5 mL.kg(‐1) with neostigmine 3 microg.kg(‐1)
Trial: 15310639
Drug: Caudal 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal 0.25% plain bupivacaine 0.5 mL.kg(‐1) with neostigmine 4 microg.kg(‐1)
Trial: 7747094
Drug: Roxithromycin 150
RxNorm normalized name: roxithromycin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin 150 mg bid for 10 days
Trial: 2687356
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg haloperidol i.v.
Trial: 1098396
Drug: methyldopa, 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methyldopa, 750 mg/day
Trial: 1098396
Drug: spironolactone, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spironolactone, 200 mg/day
Trial: 1098396
Drug: combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combined treatment with spironolactone and methyldopa